

Immunovant paid $39 million to kill batoclimab after two Phase 3 thyroid eye disease failures, betting its future on a cleaner next-generation FcRn inhibitor. The move is a case study in biotech portfolio triage as the autoimmune antibody-lowering market heats up.
Sometimes the smartest move in drug development is knowing when to fold. Immunovant just folded on batoclimab, its first-generation FcRn inhibitor, and it cost the company $39 million just to walk away clean.
That's not a write-down buried in a footnote. That's real money paid out to unwind contracts, shut down trials, and sever obligations tied to a drug the company no longer believes in. And in a biotech landscape where capital discipline separates the survivors from the obituaries, it might be the best $39 million Immunovant ever spends.
Batoclimab wasn't a total bust. It actually did what it was designed to do: block a receptor called FcRn (neonatal Fc receptor), which normally recycles antibodies in your blood. Block that receptor, and harmful autoantibodies get chewed up faster. Think of it like pulling the plug on a bathtub; the water (antibodies) drains instead of recirculating.
The drug hit its primary endpoint in a Phase 3 myasthenia gravis trial, showing meaningful symptom improvement. Early data in Graves' disease looked promising too, with over half of patients responding in a Phase 2a study. On paper, batoclimab had a future.
But there were cracks. Back in 2020, Immunovant discovered that batoclimab was causing unwanted changes in LDL cholesterol and albumin levels at certain doses. The company eventually resumed trials with adjusted dosing, but the stain never fully washed out.
Then came the kill shot: both Phase 3 trials in thyroid eye disease (TED) failed. The studies couldn't hit the bar of a 2mm or greater reduction in proptosis (eye bulging) versus placebo. Roivant, Immunovant's majority shareholder, disclosed the failures in early April 2026. By May, the review was done, and batoclimab was dead.
Killing a drug program isn't like canceling a Netflix subscription. Clinical trials involve contract research organizations, manufacturing agreements, supply chains, and site commitments that don't just vanish because you change your mind. That $39 million covers the cost of unwinding all those obligations.

A gene-edited pig kidney just kept a man alive and off dialysis for 271 days, shattering every record in xenotransplantation. With FDA approval for an expanded trial in hand, eGenesis is turning science fiction into a real answer for the 90,000 Americans stuck on the kidney transplant waiting list.


Join thousands of biotech professionals who start their day with our free, daily briefing.
The charge pushed Immunovant's R&D expenses to $360.9 million for the fiscal year ending March 31, up from $212.9 million the prior year. It's a painful line item. But the alternative, continuing to pour money into a drug with a safety asterisk and two failed pivotal trials, would have been far more expensive.
This is the kind of portfolio triage that's become a survival skill in 2026 biotech. When funding is tighter and investors reward focus over sprawl, companies are learning to cut early and cut decisively. The calculus is simple: every dollar spent on a fading asset is a dollar not spent on a rising one.
Immunovant isn't leaving the FcRn space. It's doubling down, just with a newer, theoretically better molecule called IMVT-1402.
If batoclimab was the prototype, IMVT-1402 is the production model. It hits the same target and delivers deep IgG reduction, but early data suggest it does so without the troublesome albumin and lipid changes that haunted its predecessor. In preclinical head-to-head comparisons, IMVT-1402 matched batoclimab's antibody-lowering power with a cleaner safety profile.
The pipeline is ambitious. Immunovant plans to run IMVT-1402 across roughly 10 autoimmune indications by the end of fiscal year 2026, spanning endocrinology (Graves' disease), neurology (myasthenia gravis, CIDP), rheumatology (difficult-to-treat rheumatoid arthritis, Sjögren's disease), and dermatology (cutaneous lupus). A pivotal readout in Graves' disease is expected in 2027.
Composition-of-matter patents extend through at least 2043, giving the company a long commercial runway if the drug works. And with approximately $714 million in cash on hand after the batoclimab write-off, Immunovant says it has enough fuel to reach a potential commercial launch in Graves' disease without raising more capital.
Immunovant isn't operating in a vacuum. The FcRn inhibitor class has matured rapidly, and the competition is fierce.
argenx got there first with efgartigimod (VYVGART), approved for myasthenia gravis back in 2021. It now offers both IV and subcutaneous formulations and is expanding into CIDP, ITP, pemphigus, and half a dozen other autoimmune conditions. Analysts project the franchise could generate north of $8 billion annually by the early 2030s. It's the category king, and everyone else is chasing.
Johnson & Johnson entered the ring with nipocalimab (IMAAVY), which won FDA approval for myasthenia gravis in 2025. J&J is carving out a unique angle: maternal-fetal medicine. The company is developing nipocalimab for conditions like fetal/neonatal alloimmune thrombocytopenia, where a mother's antibodies attack her baby's platelets. It's a niche that no other FcRn player has seriously pursued, and it gives J&J a differentiation story beyond the crowded autoimmune core.
UCB rounds out the approved players with rozanolixizumab (Rystiggo), also in myasthenia gravis.
For Immunovant, being late to market means the company can't compete on incumbency or brand recognition. It has to compete on profile: a cleaner drug, in indications where the big players haven't fully established themselves. Graves' disease is the strategic beachhead, a large, underserved market where FcRn inhibitors haven't yet been approved.
Wall Street seems to agree that killing batoclimab was the right call. Roivant backed up its confidence with a $349.9 million share purchase at prices well below recent trading levels.
The stock hasn't collapsed. It's held steady in the mid-$20s, suggesting investors view the discontinuation as housekeeping rather than a crisis.
That said, Immunovant remains a clinical-stage company with zero approved products and a lead asset (IMVT-1402) that still needs to prove itself in pivotal trials. The next 18 months will determine whether the company's "best-in-class" narrative holds up against real-world data.
Paying $39 million to kill your own drug sounds painful. But in biotech, the companies that survive aren't the ones that cling to every program; they're the ones that know when to let go and move on. Immunovant just made that bet. Now it has to prove the replacement was worth it.
UCB's Bimzelx just beat AbbVie's Skyrizi in a head-to-head psoriatic arthritis trial, posting the first-ever biologic superiority win on a major joint endpoint. The results could reshape how doctors pick treatments in a $13 billion market.